MindWalk (HYFT) Stock Price, News & Analysis

Company Overview

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Key Stats

• Today's Range: $1.39 to $1.50
• 50-Day Range: $1.19 to $1.97
• 52-Week Range: $0.99 to $3.25
• Volume: 210,839 shs
• Average Volume: 236,748 shs
• Market Capitalization: $65.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

MindWalk Stock Analysis - MarketRank™

MindWalk scored higher than 59% of companies evaluated by MarketBeat, and ranked 85th out of 190 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MindWalk has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

MindWalk has a consensus price target of $5.00, representing about 254.6% upside from its current price of $1.41.

Amount of Analyst Coverage

MindWalk has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MindWalk are expected to grow in the coming year, from ($0.23) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MindWalk is -7.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MindWalk is -7.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MindWalk has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.99% of the float of MindWalk has been sold short.

Short Interest Ratio / Days to Cover

MindWalk has a short interest ratio ("days to cover") of 2.79, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MindWalk has recently decreased by 12.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MindWalk does not currently pay a dividend.

Dividend Growth

MindWalk does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.52

News Sentiment

MindWalk has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.08 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for MindWalk this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 2 people have added MindWalk to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MindWalk insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.83% of the stock of MindWalk is held by insiders.

Percentage Held by Institutions

6.70% of the stock of MindWalk is held by institutions.

Company Calendar

• Last Earnings: 3/12/2026
• Today: 7/16/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HYFT
• CIK: 1715925
• Web: N/A
• Phone: (604) 806-0626
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for MindWalk: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +254.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.69 million
• Net Margins: -66.79%
• Pretax Margin: -74.38%
• Return on Equity: -69.37%
• Return on Assets: -39.74%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 3.74
• Quick Ratio: 3.64

Sales & Book Value

• Annual Sales: $17.59 million
• Price / Sales: 3.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: 3.81

Miscellaneous

• Outstanding Shares: 46,710,000
• Free Float: 43,522,000
• Market Cap: $65.86 million
• Optionable: N/A
• Beta: 0.83